Triptorelin
GnRH agonist
Triptorelin (GnRH agonist) is a hormonal & sexual research compound. GnRH agonist — a single low dose triggers an LH/FSH surge to kickstart the testicular axis (a one-shot PCT restart tool).
Triptorelin quick facts
| Reported research dose | 3.75mg,11.25mg,22.5mg 4wk,12wk,24wk |
| Route | Subq |
| Frequency | Single-dose protocols |
| Half-life | ~2-4 hrs (acute) |
| Forms | Injectable |
| Evidence level | Human (established) |
The 'one-shot' HPTA restart used in PCT — dosing precision matters, easy to misuse.
How Triptorelin works
GnRH agonist — a single low dose triggers an LH/FSH surge to kickstart the testicular axis (a one-shot PCT restart tool).
Proposed benefits
Researched for libido, hormonal signaling and reproductive / sexual function.
Can you actually get Triptorelin?
A specialist GnRH agonist. Prescriber-only, and not something to source casually.
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Triptorelin
Graded by what exists behind each claim.
✅ Clinically validated
- Approved with substantial trial data as a GnRH agonist for prostate cancer, endometriosis and central precocious puberty — all indications where the goal is to shut the reproductive axis down.
📊 Correlative data
- Community interest centers on a single-dose 'restart' protocol after androgen use, based on limited published work. That is the opposite of its licensed use, and the evidence for it is much weaker than the confidence with which it is discussed.
🧪 Theoretical / extrapolated
- A long-acting GnRH agonist. Continuous receptor stimulation causes an initial flare — a surge in LH, FSH and testosterone — followed by profound downregulation and suppression.
- The restart rationale depends entirely on catching the flare and stopping. Get the timing or dose wrong and the same mechanism delivers exactly the suppression you were trying to reverse.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Triptorelin actually does
Triptorelin is native gonadotropin-releasing hormone with one residue swapped, and that single swap is the entire drug. GnRH is a decapeptide; position 6 is glycine. Replace it with D-tryptophan and two things change at once. The D-configuration is not a substrate for the endopeptidases that cleave native GnRH at the 5-6 and 6-7 bonds, so the analog survives far longer; and the bulky indole side chain stabilizes the bend the receptor prefers, raising affinity for the GnRH receptor by roughly two orders of magnitude. One residue buys both potency and duration.
Now the part that makes this compound behave like two different drugs: the pituitary reads GnRH as a rhythm, not as a concentration. Gonadotropes are stimulated by pulses of GnRH roughly every 60–120 minutes. Continuous occupancy of the GnRH receptor does not produce continuous stimulation — it produces receptor internalization and desensitization, and the gonadotrope stops responding. That is not a side effect of chronic dosing. It is the physiology, and it is why the same molecule can be used to switch the axis on and to switch it off Magon 2011.
Phase one, hours: the flare. A single dose occupies the receptor and the gonadotrope does what it is built to do — it releases stored LH and FSH. In males that surge drives testicular Leydig cells to make testosterone; in females it recruits the follicular response. This is the phase the "restart" use is built on.
Phase two, one to three weeks: downregulation. Sustained occupancy from a depot formulation desensitizes the gonadotrope, LH and FSH fall to castrate levels, and gonadal steroid output follows. This is the phase prostate cancer therapy, endometriosis treatment and puberty blockade are built on Magon 2011.
Which phase you get is set entirely by dose and formulation, and this page's card does not distinguish them. The card lists 3.75 mg, 11.25 mg and 22.5 mg at 4, 12 and 24 weeks. Those are depot presentations, and they exist to produce phase two — sustained suppression. The single-dose "kickstart" use described in the same card is a microgram-scale subcutaneous dose, orders of magnitude smaller, given once. Reading the dose row against the mechanism row on this page gives you a protocol that achieves the opposite of what the mechanism row promises, and that is the single most important sentence here.
Cell, rodent, human — and where it stops
Step one, the acute flare in humans, which is measured to three decimal places — in children. The best human data on what a single small subcutaneous triptorelin dose does to gonadotropins comes from pediatric endocrinology, where it has become a diagnostic test for central precocious puberty.
Vukovic 2022: 60 girls, prospective, each receiving both subcutaneous triptorelin and intravenous GnRH in randomized order. Triptorelin-stimulated LH peaked at 180 minutes, and at a threshold of LH 3.4 IU/L the test had an area under the curve of 0.973, sensitivity 96.9% and specificity 89.3%. Ahn 2023 ran a larger comparison — 220 girls, 111 with central precocious puberty and 109 with idiopathic premature thelarche — and reported a peak LH threshold of 4.52 IU/L at 120 minutes giving 100% sensitivity and 95.83% specificity. Seo 2025 asked the same question in boys, comparing triptorelin against gonadorelin.
Why that literature is the right literature for this page. It is the only place where a single low subcutaneous triptorelin dose has been given to humans and LH measured serially against a comparator. It establishes the flare is real, reproducible and slower than people assume — peaking at two to three hours, not minutes — which is directly relevant to anyone timing a blood draw around a dose.
Step two, the suppression phase, which is the licensed use and is not in dispute. Depot triptorelin produces sustained gonadotropin suppression and is used for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty Magon 2011. Decades of trials, unambiguous.
Step three, adverse events at population scale. Jia 2025 analyzed 4,018 primary triptorelin reports within 18,541,994 FAERS reports from 2004 to 2024, finding 102 statistically significant adverse event terms. The time-to-onset distribution is the striking part: median 132 days (IQR 36–361), and it is bimodal — 22.59% in the first month and 25.07% after more than a year. That two-peaked shape is exactly what the two-phase pharmacology predicts: an early flare-related cluster and a late cluster from prolonged hypogonadism. The authors state plainly that these are statistical associations and do not establish causality.
The obstacle, and it is the defining one. Nobody has studied the use this page describes. There is no trial of single-dose triptorelin for restarting the male hypothalamic-pituitary-gonadal axis after exogenous androgen use. The diagnostic literature establishes the flare in girls being evaluated for precocious puberty; the oncology literature establishes suppression in older men. The extrapolation from those two to a 30-year-old man restarting his axis is exactly that — extrapolation — and the fact that it is mechanistically reasonable does not make it measured.
What would have to be true, and how you would know it was not
Three predictions, all of them cheap, and the first is the one that tells you which phase of the drug you are actually in.
1. LH and FSH at 2–3 hours after a dose is the test that says whether the flare happened. The diagnostic literature puts peak stimulated LH at 120–180 minutes after a subcutaneous dose Vukovic 2022 Ahn 2023. So draw LH/FSH at baseline and again at 2 and 3 hours. A flat LH means no flare — wrong dose, wrong product, or a pituitary that cannot respond — and those are different problems with different answers. Sampling at 30 minutes, which is what people do, can miss a flare that happened.
2. Total testosterone at 24–72 hours, and again at two weeks, is what distinguishes a restart from a shutdown. A flare should raise total testosterone within days. The prediction that cuts against the product is the second draw: if the dose was large enough or repeated, the same molecule desensitizes the gonadotrope and testosterone falls below baseline by week two or three. One molecule, two opposite results, and the only way to know which one you produced is the second blood draw. Take SHBG at the same time so free testosterone can be estimated rather than guessed.
3. Estradiol should be measured, not assumed. A testosterone surge raises substrate for aromatase, so estradiol follows testosterone up, and the symptoms people attribute to the peptide are frequently estradiol symptoms. Use the sensitive assay in men; the standard immunoassay is unreliable at male concentrations, which is a measurement problem this site's marker pages cover in detail.
What nobody has tested yet
Four things nobody has tested about the way this compound is actually used.
Nobody has published a dose-response for the flare in adult men. The entire serial-LH literature is pediatric Vukovic 2022 Ahn 2023 Seo 2025. What a given microgram dose does to LH in a 30-year-old man with a suppressed axis has never been measured, so the doses in circulation come from analogy and forum consensus rather than from a curve.
Nobody knows where the flare-to-suppression threshold sits. The two phases are separated by dose and duration, and nobody has established the boundary in a person using this for a restart. That is the most consequential unknown attached to the compound, because crossing it produces the opposite of the intended effect and the user cannot feel the difference for weeks.
Nobody has compared it head to head with hCG or with a SERM for axis recovery. Those are the alternatives, they work through different points in the same axis, and the comparison has never been run. A three-arm study with LH, FSH and total testosterone at 2, 6 and 12 weeks would answer the question the entire use case rests on.
Nobody has explained the late FAERS signals. Jia 2025 found unexpected terms, including behavioral and cognitive ones, and a quarter of all reports arriving after a year. Whether those reflect prolonged hypogonadism, the underlying disease, or reporting artifact is unresolved, and disentangling them would require a cohort with baseline hormone data that nobody has assembled.
Triptorelin — its own safety story, not its class's
The class block above is generic. Here is what belongs to this molecule.
The flare is the risk in the licensed setting, and it is the point in the unlicensed one. In advanced prostate cancer the initial testosterone surge can worsen disease, which is why an antiandrogen is given first — standard oncology practice built entirely on the two-phase pharmacology described above Magon 2011. The same surge is what the restart use is trying to produce. Anyone with an undiagnosed prostate problem is deliberately generating the exact hormonal event oncology takes trouble to block. That is not a reason for alarm; it is a reason to know your baseline before you start.
The dose row on this page is the practical hazard. Milligram depot doses produce sustained suppression, not a restart. Someone using a depot presentation for the purpose the card describes would achieve chemical castration for one to six months and would not know for several weeks. This is a documentation problem rather than a pharmacological one, and it is the reason the mechanism section above spells the two phases out separately.
What the population-scale data actually shows. Jia 2025: 102 significant adverse-event signals across 4,018 reports, with a bimodal onset. The early peak is consistent with the flare; the late peak is consistent with sustained hypogonadism — which brings bone density loss, mood change and metabolic drift, all of which are well documented for this drug class in its licensed long-term use. A one-off microgram dose does not carry that risk. A repeated one does, and nobody has defined how many is too many.
The bone question, stated once. Prolonged gonadotropin suppression reduces bone mineral density; this is why puberty-blocking and oncology protocols monitor it. Anyone who has crossed into phase two, deliberately or accidentally, has entered that risk category, and there is no blood marker that reports it — the measurement is a DEXA scan.
Sources read for this page
- Vukovic R, et al. Triptorelin stimulated luteinizing hormone concentrations for diagnosing central precocious puberty: study of diagnostic accuracy. Endocrine 2022 · PMID 34826116
- Ahn J, et al. Use of the Subcutaneous Triptorelin Stimulation Test for Diagnosis of Central Precocious Puberty. Children (Basel) 2023 · PMID 38002921
- Seo JH, et al. Is the triptorelin stimulation test comparable to the gonadorelin stimulation test in diagnosing central precocious puberty in boys?. Annals of Pediatric Endocrinology and Metabolism 2025 · PMID 41207293
- Jia W, et al. Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data. Scientific Reports 2025 · PMID 40890214
- Magon N. Gonadotropin releasing hormone agonists: Expanding vistas. Indian Journal of Endocrinology and Metabolism 2011 · PMID 22028996
Triptorelin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on the top of the reproductive axis, and which direction they push depends on how they are given. hCG and gonadorelin stimulate; kisspeptin stimulates upstream of GnRH. Continuous GnRH agonism (triptorelin) paradoxically SUPPRESSES after an initial flare, because sustained signaling desensitizes the receptor. Cetrorelix is a straightforward antagonist and suppresses immediately.
- The predicted harm follows the direction: stimulation raises testosterone and estradiol together, so aromatization-driven effects arrive with it. Suppression produces a hypogonadal state — low libido, fatigue, mood change, and bone loss if prolonged.
- The initial FLARE on a GnRH agonist is the specific thing to know about: hormones rise sharply before they fall, and symptoms can transiently worsen.
What has actually been reported
- hCG is well characterized in fertility medicine — gynecomastia and fluid retention from the estradiol rise are the common complaints.
- GnRH agonist flare is documented and clinically managed in oncology with an antiandrogen during the first weeks.
How to reduce the risk
Same mechanism as the prediction.
- If using hCG alongside an androgen to preserve testicular function, lower and more frequent beats large and infrequent — the estradiol spike tracks the dose size.
- Anything suppressing the axis for more than a few months needs a bone density conversation, not just a hormone panel.
What it does to your bloodwork
A fact about the assay.
- LH and FSH, total and free testosterone, sensitive estradiol (these raise it more than people expect), and a semen analysis if fertility is the reason you are running it.
Don't run this if
- You have a hormone-sensitive cancer, unless this is being directed by an oncologist — in which case it is their protocol, not one to self-manage.
The honest unknown
- Kisspeptin analogs are early in human study. The axis effect is real and well demonstrated acutely; the consequences of repeated long-term use are not established.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Triptorelin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Triptorelin moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Triptorelin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Triptorelin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| LH & FSH | A GnRH agonist flares then suppresses these. Timing changes the meaning |
| Total Testosterone | The downstream result of that flare-then-crash |
| Estradiol, Sensitive (LC/MS-MS) | Follows testosterone up and back down |
The Post-Cycle / Recovery & Fertility panel covers these in one order — 9 markers, $184.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Triptorelin — frequently asked questions
What is Triptorelin?
Triptorelin (GnRH agonist) is a hormonal & sexual research compound. GnRH agonist — a single low dose triggers an LH/FSH surge to kickstart the testicular axis (a one-shot PCT restart tool).
Is the full Triptorelin protocol on this page?
The reported research dose is on this page, along with how Triptorelin works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Triptorelin?
Triptorelin has an approximate half-life of ~2-4 hrs (acute), which is part of what determines how often it's dosed.
What's the evidence behind Triptorelin?
Current evidence level: Human (established). Triptorelin is offered for research purposes only and is not an approved medicine.
What Triptorelin is used for
Triptorelin appears under 2 goals in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.